Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 30, 2012
Principal Office: River Edge, New Jersey
This filing reports a significant regulatory milestone achieved by the company regarding its Hemodiafiltration system.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory event and does not contain financial statements or performance data.
Material Changes
Regulatory Clearance: On April 30, 2012, Nephros, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Product Scope: The clearance permits the marketing of the company's Hemodiafiltration system for the treatment of chronic renal failure.
Usage Conditions: The system is approved for use with UF controlled dialysis machines capable of producing ultrapure dialysate in accordance with current AAMI/ANSI/ISO standards in the United States.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) announcing the FDA clearance but does not provide specific forward-looking guidance, financial outlook, or detailed risk factors within the body of this 8-K.
Unusual Items: None reported beyond the regulatory approval.
Investor Verification Checklist
- Verify the specific technical requirements for the "UF controlled dialysis machines" mentioned in the FDA clearance to assess market compatibility.
- Review the attached press release (Exhibit 99.1) for details on commercialization timelines and pricing strategy.
- Confirm the company's current cash position and runway, as this filing does not disclose liquidity status.
- Monitor subsequent filings for updates on product launch and initial sales figures.